Some biotech investors had probably never heard of exosomes until Codiak’s chief executive, Doug Williams, made his pitch at the JP Morgan conference two weeks ago. But the area has been gaining traction, and Jazz’s $56m up-front payment to Codiak is its biggest endorsement to date. Roche and Boehringer Ingelheim have also bought into rival technologies, which broadly seek to use exosomes as delivery vehicles for proteins, small molecules, RNA and other therapeutics. Naturally occurring exosomes are vesicles that bud off from many mammalian cells and are subsequently internalised by other cells, along with their cargo, hence their role in cell-cell communication.
Avalon GloboCare and Genexosome Technologies announce discovery and development of first saliva-based exosomal biomarker “miR-185” as dual diagnostic and therapeutic target for Oral Cancer
16 days ago
NX Prenatal and Milu Labs Announce Strategic Collaboration to Commercialize Exosome-Based Preterm Birth Risk Test in Asia
29 days ago
San Diego Blood Chip Maker BioFluidica Awarded Two NIH/NCI Grants for Isolation of Cell-Free DNA and Exosomes on Its Single Liquid Biopsy Platform
January 9, 2019